| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $2,000,001 | 1 | 100 |
Sells | $0 | 0 | 0 |
| Invus Global Management, LLC | 1 | $2M | 0 | $0 | $2M |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Over the last 12 months, insiders at Lexicon Pharmaceuticals, Inc. have bought $2M and sold $0 worth of Lexicon Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Lexicon Pharmaceuticals, Inc. have bought $42.48M and sold $158,440 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Invus Global Management, LLC () — $2M.
The last purchase of 1,538,462 shares for transaction amount of $2M was made by Invus Global Management, LLC () on 2026‑02‑02.
| 2026-02-02 | Invus Global Management, LLC | 1.54M 0.4403% | $1.30 | $2M | +4.59% | |||
| 2023-11-16 | COATS LONNEL | Chief Executive Officer | 90,000 0.0365% | $1.05 | $94,797 | +60.85% | ||
| 2023-11-10 | COATS LONNEL | Chief Executive Officer | 10,000 0.0041% | $1.01 | $10,100 | +69.31% | ||
| 2023-10-12 | DEBBANE RAYMOND | director | 148,820 0.0604% | $1.03 | $153,805 | +61.54% | ||
| 2023-10-11 | DEBBANE RAYMOND | director | 342,874 0.1415% | $1.08 | $370,784 | +57.01% | ||
| 2023-10-10 | DEBBANE RAYMOND | director | 508,306 0.2365% | $1.14 | $579,367 | +50.00% | ||
| 2023-09-14 | WADE JEFFREY L | President and CFO | 10,000 0.0042% | $1.38 | $13,800 | +25.37% | ||
| 2023-08-04 | McDermott Wendy | VP, Human Resources | 6,000 0.0024% | $1.84 | $11,040 | -9.89% | ||
| 2023-06-29 | COATS LONNEL | Chief Executive Officer | 10,000 0.0053% | $2.16 | $21,600 | -21.66% | ||
| 2023-06-26 | COATS LONNEL | Chief Executive Officer | 10,000 0.0053% | $2.18 | $21,792 | -21.43% | ||
| 2023-06-23 | COATS LONNEL | Chief Executive Officer | 10,000 0.0056% | $2.50 | $24,950 | -27.64% | ||
| 2023-06-23 | McDermott Wendy | VP, Human Resources | 10,000 0.0054% | $2.43 | $24,300 | -27.64% | ||
| 2023-06-22 | COATS LONNEL | Chief Executive Officer | 40,000 0.0211% | $2.31 | $92,400 | -25.86% | ||
| 2023-06-20 | WADE JEFFREY L | President and CFO | 12,000 0.0063% | $2.33 | $28,000 | -27.12% | ||
| 2023-06-05 | Artal International S.C.A. | 27.78M 15.0418% | $2.60 | $72.22M | -32.28% | |||
| 2022-08-05 | Invus Advisors, L.L.C. | 2.43M 1.2253% | $2.50 | $6.07M | -18.02% | |||
| 2022-08-05 | DEBBANE RAYMOND | 147,390 0.0744% | $2.50 | $368,475 | -18.02% | |||
| 2022-08-01 | Invus Advisors, L.L.C. | 16.17M 9.7545% | $2.50 | $40.43M | -2.11% | |||
| 2022-08-01 | DEBBANE RAYMOND | 1.97M 1.1852% | $2.50 | $4.91M | -2.11% | |||
| 2021-03-15 | Sale | Tessmer James F | VP, Finance & Accounting | 22,912 0.0161% | $6.92 | $158,440 | -35.08% |
| Invus Global Management, LLC | 1538462 0.389% | $2.03M | 1 | 0 | ||
| Ulys, LLC | 10 percent owner | 135327888 34.2199% | $178.63M | 4 | 0 | <0.0001% |
| Artal International S.C.A. | 78634381 19.884% | $103.8M | 4 | 0 | +10.29% | |
| Invus Advisors, L.L.C. | 50859331 12.8606% | $67.13M | 2 | 0 | <0.0001% | |
| Invus Public Equities, L.P. | 32259461 8.1573% | $42.58M | 27 | 0 | <0.0001% | |
| Invus C.V. | 30248505 7.6488% | $39.93M | 3 | 0 | +21.63% | |
| DEBBANE RAYMOND | director | 1340847 0.3391% | $1.77M | 7 | 0 | +18% |
| COATS LONNEL | Chief Executive Officer | 914359 0.2312% | $1.21M | 12 | 0 | +6.36% |
| SANDS ARTHUR T | Pres & CEO | 682662 0.1726% | $901,113.84 | 0 | 4 | |
| WADE JEFFREY L | President and CFO | 264341 0.0668% | $348,930.12 | 3 | 0 | +1.38% |
| SOBECKI CHRISTOPHER J | director | 137293 0.0347% | $181,226.76 | 2 | 0 | <0.0001% |
| ZAMBROWICZ BRIAN P | EVP, Research | 101600 0.0257% | $134,112.00 | 0 | 2 | |
| Tessmer James F | VP, Finance & Accounting | 71766 0.0181% | $94,731.12 | 1 | 4 | +91.67% |
| BARKER SAM L | director | 52187 0.0132% | $68,886.84 | 4 | 0 | +14.18% |
| GREGORY JULIA P | EVP, Corp Dev and CFO | 50200 0.0127% | $66,264.00 | 0 | 6 | |
| McDermott Wendy | VP, Human Resources | 28478 0.0072% | $37,590.96 | 2 | 0 | <0.0001% |
| ROSE CLAYTON STUART | director | 25000 0.0063% | $33,000.00 | 2 | 0 | <0.0001% |
| Mills Barry | director | 25000 0.0063% | $33,000.00 | 1 | 0 | <0.0001% |
| Santini Alexander A | EVP and CCO | 18661 0.0047% | $24,632.52 | 2 | 0 | <0.0001% |
| RIGGS RANDALL B | SVP, Corp Licensing | 15000 0.0038% | $19,800.00 | 0 | 2 | |
| CASKEY C THOMAS | director | 6300 0.0016% | $8,316.00 | 5 | 0 | +5.92% |
| NIES ALAN S | director | 5000 0.0013% | $6,600.00 | 1 | 0 | <0.0001% |
| PERSON CHRISTOPHE | VP Informatics | 0 0% | $0 | 0 | 2 | |
| PIGGOTT JAMES R PHD | SVP of Pharm Bio | 0 0% | $0 | 0 | 5 |
$3,611,891 | 113 | 13.40% | $568.07M | |
Lexicon Pharmaceuticals, Inc. (LXRX) | $860,541,348 | 82 | -5.10% | $522.02M |
$63,049,419 | 31 | 2.87% | $591.5M | |
$112,238,340 | 19 | 39.16% | $482.32M | |
$46,858,891 | 18 | -11.58% | $576.47M | |
$3,556,951 | 18 | 9.64% | $497.63M | |
$59,102,045 | 17 | 8.52% | $602.76M | |
$8,069,667 | 13 | -13.57% | $506.32M | |
$57,263,116 | 11 | -8.37% | $485.42M | |
$19,167,169 | 10 | 28.48% | $576.83M | |
$75,069,528 | 10 | 19.77% | $568.45M | |
$49,165,200 | 7 | 12.92% | $599.48M | |
$94,000,000 | 7 | -20.84% | $597.49M | |
$88,549,962 | 5 | -16.91% | $483.55M | |
$1,746,565 | 4 | -29.05% | $510.69M | |
$144,224 | 4 | 21.31% | $483.6M | |
$58,352 | 4 | -43.78% | $495.18M | |
$2,857,000 | 2 | -5.23% | $517.81M | |
$300,016 | 1 | -50.33% | $539.17M |
| Increased Positions | 49 | +30.82% | 15M | +5.74% |
| Decreased Positions | 61 | -38.36% | 9M | -3.5% |
| New Positions | 19 | New | 5M | New |
| Sold Out Positions | 24 | Sold Out | 2M | Sold Out |
| Total Postitions | 147 | -7.55% | 261M | +2.24% |
| Artal Group S.A. | $155,246.00 | 37.52% | 136.18M | 0 | 0% | 2025-09-30 |
| Siren, L.L.C. | $44,368.00 | 10.72% | 38.92M | 0 | 0% | 2025-09-30 |
| Fmr Llc | $44,095.00 | 10.66% | 38.68M | +542,213 | +1.42% | 2025-09-30 |
| Vanguard Group Inc | $10,855.00 | 2.62% | 9.52M | +670,838 | +7.58% | 2025-09-30 |
| Millennium Management Llc | $4,367.00 | 1.06% | 3.83M | +2M | +133.11% | 2025-09-30 |
| Blackrock, Inc. | $3,870.00 | 0.94% | 3.39M | +40,303 | +1.2% | 2025-09-30 |
| Sessa Capital Im, L.P. | $3,420.00 | 0.83% | 3M | 0 | 0% | 2025-09-30 |
| Citadel Advisors Llc | $3,003.00 | 0.73% | 2.63M | +3M | New | 2025-09-30 |
| Cibc Private Wealth Group Llc | $2,736.00 | 0.66% | 2.4M | -50,143 | -2.05% | 2025-09-30 |
| Geode Capital Management, Llc | $2,734.00 | 0.66% | 2.4M | +20,229 | +0.85% | 2025-09-30 |